Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody‐mediated rejection
Authors:
- 27 January 2011
- journal article
- Published by Wiley in Nephrology
- Vol. 16 (2) , 239-242
Abstract
Intravenous immunoglobulin (IVIg) therapy for antibody‐mediated rejection (AMR) is increasing and is associated with a small but significant incidence of thrombosis. We determined thrombosis rates in patients treated with high‐dose IVIg for AMR before and after alteration of an infusion protocol. The newer protocol introduced routine administration of aspirin 300 mg, enoxaparin 1 mg/kg, intravenous hydration and a maximum infusion rate of 100 mg/kg per hour (previously 200 mg/kg per hour). Nine thromboses in 275 infusions occurred before the protocol alteration (event rate 3.3%). Two were arterial thromboses including an acute myocardial infarct and a renal transplant artery thrombosis, which resulted in infarction of 2/3 of the graft. Seven venous thromboses occurred, six in arteriovenous fistulae and one case with bilateral above knee deep venous thromboses. Significant associations with thromboses were seen with higher IVIg dose and male sex. In the 6 months since the introduction of the new infusion protocol, 74 infusions have been administered with no thrombotic events. There have been no significant bleeding or fluid overload side‐effects. Infusion times, however, have been doubled. A slower rate of infusion combined with antiplatelet and anticoagulation has thus far eliminated the small but significant IVIg‐related thrombosis rate previously observed in our patients treated for AMR without resulting in significant side‐effects. Further study is now required to define which elements of this protocol are essential.Keywords
This publication has 19 references indexed in Scilit:
- The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice GuidelineTransfusion Medicine Reviews, 2010
- Excellent Renal Allograft Survival in Donor-Specific Antibody Positive Transplant Patients—Role of Intravenous Immunoglobulin and Rabbit Antithymocyte GlobulinTransplantation, 2009
- The Spectrum of Antibody-Mediated Renal Allograft Injury: Implications for TreatmentAmerican Journal of Transplantation, 2008
- Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseasesClinical Rheumatology, 2007
- Adverse effects of treatment with intravenous immunoglobulins for neurological diseasesJournal of Neurology, 2006
- Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literatureBritish Journal of Dermatology, 2006
- Intravenous Immunoglobulin as a Treatment for BK Virus Associated NephropathyTransplantation, 2006
- Review: intravenous immunoglobulin therapy and thromboembolic complicationsLupus, 2005
- Venous and arterial thrombosis following administration of intravenous immunoglobulinsBlood Coagulation & Fibrinolysis, 2005
- POSTTRANSPLANT THERAPY USING HIGH-DOSE HUMAN IMMUNOGLOBULIN (INTRAVENOUS GAMMAGLOBULIN) TO CONTROL ACUTE HUMORAL REJECTION IN RENAL AND CARDIAC ALLOGRAFT RECIPIENTS AND POTENTIAL MECHANISM OF ACTION1Transplantation, 1998